Further, JPHYD yielded significant RFS advantages for males, patients aged < 60 years, patients with BCLC A, single tumor, tumor distribution on one-side, maximum tumor diameter ≤ 8 cm, low-grade tumor differentiation, presence of MVI and cirrhosis, AFP < 400, HBV infection, HBV DNA ≤ 1,000, ICG ≤ 10%, or Child-Pugh A grade disease, regardless of whether they received comprehensive therapy (Figure 6B). The gene discussed is AFP; the disease is neoplasm.